Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Black Diamond Therapeutics (BDTX) Total Non-Current Liabilities (2018 - 2020)

Black Diamond Therapeutics' Total Non-Current Liabilities history spans 3 years, with the latest figure at $21.9 million for Q4 2020.

  • For Q4 2020, Total Non-Current Liabilities rose 350.59% year-over-year to $21.9 million; the TTM value through Dec 2020 reached $21.9 million, up 350.59%, while the annual FY2020 figure was $21.9 million, 350.59% up from the prior year.
  • Total Non-Current Liabilities reached $21.9 million in Q4 2020 per BDTX's latest filing, up from $19.1 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $21.9 million in Q4 2020 to a low of $2.6 million in Q4 2018.
  • Average Total Non-Current Liabilities over 3 years is $10.4 million, with a median of $6.9 million recorded in 2020.
  • Peak YoY movement for Total Non-Current Liabilities: soared 88.85% in 2019, then skyrocketed 350.59% in 2020.
  • A 3-year view of Total Non-Current Liabilities shows it stood at $2.6 million in 2018, then skyrocketed by 88.85% to $4.9 million in 2019, then surged by 350.59% to $21.9 million in 2020.
  • Per Business Quant, the three most recent readings for BDTX's Total Non-Current Liabilities are $21.9 million (Q4 2020), $19.1 million (Q3 2020), and $6.3 million (Q2 2020).